Now reading Entry 067 / 102 Last revised Apr 13, 2026 8 sources Methodology →
A specimen of the Metabolic drawer Drawer A · Metabolic

PF-08653944

Investigational

Pfizer's once-monthly GLP-1 receptor agonist peptide (Metsera MET097 lineage). The once-monthly Phase 2b (SOLIS-1, NCT07575932) is recruiting with no reported results yet, and the molecule has no published efficacy data. A Phase 3 program (VESPER-4/5/6) is enrolling, positioning it as a potential long-acting alternative to weekly GLP-1 therapies.

Pfizer GLP-1 · Monthly GLP-1

Research evidence
Moderate

5 human studies

Preclinical
38%
Clinical
63%

Based on 8 cited sources

Evidence Score42/100
Early / limited
Research Depth21/100
Mechanism70/100
Plausibility87/100
Global Coverage24/100
Community Experience6/100
EffectivenessNot Established

Demonstrated effect magnitude — not a recommendation or safety claim.

PF-08653944 is a real Pfizer once-monthly GLP-1 receptor agonist (Metsera MET097 lineage) verified in ClinicalTrials.gov (7 registered trials, accessed 2026-06-26); it has ZERO PubMed publications. CRITICAL: the dossier body claims a "completed Phase 2b" with "12.3% weight loss at 28 weeks," but the actual Phase 2b SOLIS-1 (NCT07575932) is only RECRUITING with no posted results (has_results=false; primary endpoint at Week 48, completion 2028) — no reported human efficacy result exists for this molecule. Research Depth 21: registered Phase 1 PK/BA/gastric-emptying/ hepatic studies (NCT07400679/07508241/07519135) and an enrolling Phase 2b, but zero reported human outcomes (1A=9 human trials underway/none reported; 1B=3 no study to appraise; 1C=2 reported human N~0; 1D=4 intended-direct only; 1E=3 unpublished preclinical package). Mechanism 70: GLP-1R is a validated target with binding+functional confirmation at class level (2A=30), full incretin->insulin/glucagon/gastric-emptying/hypothalamic pathway characterized for the class (2B=24), class-level dose-response (2C=8), in-vivo mammalian confirmation (2D=8) — molecule-specific binding/KO data unpublished. Plausibility 87: GLP-1 RA -> weight loss is the best-supported causal chain in metabolic pharmacology, mechanism->surrogate proven and surrogate->benefit strongly inferred for this molecule (3A=30), fully coherent (3B=24), strongest class/analogy support from semaglutide/ tirzepatide/liraglutide (3C=20), tightly scoped single-mechanism claim (3D=13). Global Coverage 24: single Pfizer/Metsera program, no independent replication (4A=5), multi-site but one-sponsor footprint (4B=10), <5 studies and zero publications (4C=4), active regulator trial registration (4D=5). Community Experience 6: trial-only, no documented real-world use or reports (5A=2/5B=2/5C=0/5D=2). Effectiveness not-established: no reported or published human efficacy estimate for PF-08653944 and no community effect signal; the dossier's 12.3%/28-week figure is unverified and not traceable to any reported PF-08653944 trial (flag for content correction).

Scored June 2026 How we rate →
~
Evidence Level
moderate
Not approved for human use by any regulatory agency
Limited human clinical trial data
Consult a healthcare provider before use
Not FDA Approved WADA Prohibited
Identity
Also Known As
Pfizer GLP-1 • Monthly GLP-1

How It Works (Simplified)

PF-08653944 is a long-acting GLP-1 receptor agonist designed for once-monthly subcutaneous administration. Like other GLP-1 receptor agonists, it mimics the incretin hormone GLP-1 to reduce appetite, slow gastric emptying, and improve glycemic control. The monthly dosing interval represents a significant advancement over current weekly injectable options.

Scientific Pathways

GLP-1 Receptor Activation: Binds to and activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and activating central satiety pathways in the hypothalamus.

Extended Duration: Pfizer’s proprietary formulation technology enables sustained GLP-1 receptor engagement over approximately 30 days from a single injection, potentially improving treatment adherence compared to weekly alternatives.

Clinical Evidence

No published efficacy data. PF-08653944 has zero PubMed-indexed publications and no posted ClinicalTrials.gov results. No human weight-loss figure for the once-monthly molecule has been reported, so any specific percentage should be treated as unverified.

Once-monthly Phase 2b (ongoing): The dedicated Phase 2b dose-finding study for once-monthly PF-08653944 — SOLIS-1 (NCT07575932), an umbrella study also evaluating the amylin analog PF-08653945 — is recruiting, with its primary body-weight endpoint at Week 48 and no results yet.

Weekly MET097 lineage: PF-08653944 is the once-monthly formulation of Metsera/Pfizer’s MET097 (a fully-biased, ultra-long-acting GLP-1 receptor agonist). The once-weekly MET097 has completed earlier-stage trials, including a Phase 1/2 study (NCT06857617) and a 28-week Phase 2b (VESPER-1, NCT06712836) — but these test the weekly formulation, and neither has posted results on ClinicalTrials.gov.

Phase 3 program (ongoing): A Phase 3 program is now enrolling, including VESPER-5 in type 2 diabetes (NCT07400653), VESPER-6 in overweight/obesity (NCT07595549), and VESPER-4 (NCT07311850). These trials are recruiting; none has reported results.

Safety Profile

No trial-reported safety data have been posted for once-monthly PF-08653944. Based on the GLP-1 class, the expected adverse event profile is gastrointestinal — nausea, vomiting, and diarrhea. Monthly dosing may produce a different temporal pattern of side effects compared with weekly formulations, but this remains a hypothesis until the ongoing Phase 2b and Phase 3 trials report. Full safety characterization awaits those data.

Important Limitations

  • No published or trial-reported efficacy data for once-monthly PF-08653944; any specific weight-loss percentage is unverified
  • The dedicated Phase 2b (SOLIS-1) is still recruiting; Phase 3 trials are enrolling but have not reported results
  • Monthly injection may limit dose titration flexibility
  • Not available outside clinical trials
  • Pfizer’s previous oral GLP-1 candidate (danuglipron) was discontinued, raising execution questions
Synergistic
Compatible
Caution
Avoid

Both are GLP-1 receptor agonists. Co-administration would provide redundant GLP-1 agonism with increased risk of GI adverse events.

Both target GLP-1 receptors. Combining would create overlapping mechanisms with potential for severe GI side effects.

Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.

8 Sources 5 Human 3 Preclinical

Full reference list available on request. All citations link to PubMed for verification.

This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.

For complete methodology details, see our Methodology page.

Important Disclaimer

This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.

Get Research Alerts

New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.

No spam. Unsubscribe anytime.

Compare PF-08653944

Related Peptides

Metabolic

5-Amino-1MQ

5-Amino-1-Methylquinolinium · NNMT Inhibitor

A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.

See dossier
Metabolic

Amycretin

NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin

A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.

See dossier
Metabolic

AOD-9604

Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191 · hGH Fragment 176-191

A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.

See dossier
Metabolic

Cagrilintide

AM833 · NN9838

A long-acting amylin analog developed by Novo Nordisk for weight management. Studied in Phase 3 trials as CagriSema (combination with semaglutide). The Phase 3 REDEFINE 1 trial showed -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.

See dossier
Metabolic

CagriSema

Cagrilintide-Semaglutide · NNC0174-0833

A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.

See dossier
Metabolic

CT-388

RG-6912

A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.

See dossier

Related Content